Debiopharm and Forge a Strategic Partnership to Propel Cancer Drug Development with AI Digital Cell Clones

LAUSANNE, Switzerland & SAN DIEGO–(BUSINESS WIRE)–Debiopharm, an independent biopharmaceutical company headquartered in Switzerland, and (TNL), a trailblazer in AI Digital Cells Lab in USA, are pleased to announce a collaborative partnership aimed at advancing the development of a cutting-edge cancer drug. This strategic alliance leverages the unique capabilities of…
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks